Ullah etal_ISCIENCE-D-23-05286: Bioluminescence Imaging Reveals Enhanced SARS-CoV-2 Clearance in Mice with Combinatorial Regimens

Published: 29 November 2023| Version 2 | DOI: 10.17632/n9ztbbbstm.2
Contributors:
,

Description

Direct acting antivirals (DAAs) represent critical tools for combating SARS-CoV-2 variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence imaging to evaluate therapeutic efficacy of DAAs that target SARS-CoV-2 RNA-dependent RNA polymerase (favipiravir, molnupiravir) or Main protease (nirmatrelvir) against Delta or Omicron VOCs in K18-hACE2 mice. Nirmatrelvir displayed the best efficacy followed by molnupiravir and favipiravir in suppressing viral loads in the lung. Unlike neutralizing antibody treatment, DAA monotherapy regimens did not eradicate SARS-CoV-2 in mice but combining molnupiravir with nirmatrelvir exhibited superior additive efficacy and led to virus clearance. Furthermore, combining molnupiravir with Caspase-1/4 inhibitor mitigated inflammation and lung pathology whereas combining molnupiravir with COVID-19 convalescent plasma demonstrated synergy, rapid virus clearance and 100% survival. Thus, our study provides insights into in vivo treatment efficacies of DAAs and other effective combinations to bolster COVID-19 therapeutic arsenal. The excel files are arranged figure wise and contain the raw data used to generate figures shown in the manuscript "Ullah etal_ISCIENCE-D-23-05286"

Files

Steps to reproduce

Please see the Key resource table for reagent list and Method details in the manuscript Ullah etal_ISCIENCE-D-23-05286. The Excel file details the steps used to calculate Bliss index scores for combinatorial regimens.

Institutions

Categories

Inflammation, Mouse, Antiviral Drug, Neutralizing Antibody, Bioluminescence, Drug Combination, Synergism, Additive Interaction, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

Funders

Licence